The Food and Drug Administration recently granted marketing approval and a label expansion to Ariad Pharmaceuticals' drug Iclusig.
The FDA first approved the drug to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia in December 2012.
The drug was approved through the FDA's accelerated approval program, which allows the agency to approve drugs intended to treat serious or life-threatening diseases based on clinical data demonstrating the drug is likely to have clinical benefit for patients.
Iclusig can now be marketed and used to treat multiple types and stages of leukemia.
The expanded approval comes after results of a four-year follow up study of Iclusig demonstrated the clinical benefits of the drug.
More articles on supply chain:
DEA bans furanyl fentanyl
4 threats to the US blood supply
Court orders contracted pilots for Amazon, DHL to return to work after strike